How the proteins ARF and ADAR1 affect triple-negative breast cancer
Antagonistic role of ARF and ADAR1 in triple-negative breast cancer
This project looks at whether changing ARF and ADAR1 levels can boost immune signals and make triple-negative breast cancer cells more likely to die for people with TNBC.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11258917 on NIH RePORTER |
What this research studies
Researchers will work with triple-negative breast cancer cell lines and molecular tests to see how ARF and ADAR1 interact and control type I interferon (immune) signaling. They will reduce ADAR1 and change ARF levels to observe effects on cancer cell survival and markers of immune recognition. The team will test whether ARF traps ADAR1 in the nucleolus and whether that trapping prevents ADAR1 from blocking immune signals. Findings will be compared to tumor-related data to look for biomarkers that could point to patient groups most likely to benefit.
Who could benefit from this research
Good fit: People with triple-negative breast cancer, especially tumors showing loss of ARF and p53 mutation, would be most relevant to these findings.
Not a fit: Patients with non–triple-negative breast cancer or tumors that retain ARF and normal p53 are less likely to benefit from this specific line of work.
Why it matters
Potential benefit: If successful, this could point to new biomarkers or treatment approaches that make TNBC tumors more sensitive to immune attack and more likely to die.
How similar studies have performed: Other studies have shown ADAR1 controls interferon responses and that targeting ADAR1 can sensitize tumors, but the ARF–ADAR1 interaction in TNBC is a new and untested finding.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Weber, Jason — Washington University
- Study coordinator: Weber, Jason
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.